Please assess the completion status of the following clinical trial:

Trial Title: Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with impaired glucose tolerance (2 h glucose between 140 - 199 mg / dL) that after 1 year of treatment with metformin at a dose of 1700 mg daily + lifestyle modifications don't achieve normoglycemia.~* Patients who accept to participate in the study and sign informed consent.~Exclusion Criteria:~* Patients with type 2 Diabetes diagnosted previuosly or detected during the OGTT~* Serum creatinine \> 1.6 mg/dL~* Hypertriglyceridemia very high (\>500 mg/dL)~* Pregnancy~* Systolic blood pressure \> 180 mmHg or Diastolic blood pressure \>105 mmHg (patients could be re-screened after blood pressure control)~* Excessive alcohol intake, acute or chronic~* Medications or medical conditions that affect glucose homeostasis (thiazides, beta blockers, glucocorticoids for systemic use, weight-reducing drugs or anorexigenics, Cushing's syndrom, Thyrotoxicosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin + Metformin and lifestyle (Type: EXPERIMENTAL): Patients with impaired glucose tolerance randomly assigned to linagliptin 2.5 mg + metftormin 850 mg every 12 hours during 6 months.
- Metformin (Type: ACTIVE_COMPARATOR): Patients with impaired glucose tolerance randomly assigned to metftormin 850 mg every 12 hours during 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).